GLP-1 field notes
A clearer record of your GLP-1 routine
A medication name, a dose, and a date are three different pieces of information. This guide covers semaglutide, tirzepatide, and liraglutide. This GLP-1 reference brings them into view together: label-based schedules explain the published sequence, the GLP-1 tracker page describes how to keep a record, and symptom pages identify exactly which evidence supports a reported percentage. Begin from the question you have, then follow the source and the relevant product presentation.
Updated . Sources checked against the cited documents on 19 November 2026.

Find the product, then keep the route visible
Semaglutide appears in Ozempic, Wegovy, and Rybelsus labeling. Tirzepatide is sold as Mounjaro and Zepbound, while the liraglutide reference here focuses on Saxenda. Those names help identify which prescribing information a page describes. They do not imply that products with the same ingredient share every dose, device instruction, or route. Each schedule page begins with the generic ingredient and names the label it covers. Ozempic labelWegovy labelRybelsus labelMounjaro labelZepbound labelSaxenda label
These labels cover weekly injections, a daily injection, and an oral tablet. In particular, oral semaglutide deserves its own timing context. A tablet strength is not a syringe marking, and a daily reminder does not mean the same thing as a weekly injection reminder. Selecting the correct route is part of making the rest of a medication record understandable. Ozempic labelWegovy labelRybelsus labelMounjaro labelZepbound labelSaxenda label
Read a schedule as a reference
The schedule pages retain the conditions around a labeled increase instead of presenting every available strength as an automatic next step. They distinguish initiation from maintenance and explain where the same ingredient has multiple label schedules. The tables use explicit timing units so that a week-long phase is not confused with the frequency of administration. They are educational references rather than individual prescriptions.
The units page explains how mg, mL and U-100 units relate, and lists the volume of each labeled pen, vial and syringe dose. Its examples show why 20 U-100 units can contain different milligram amounts. A calculation cannot choose a clinical amount, identify an unknown vial, or convert an oral tablet into an injection equivalent. The linked calculators use the values entered to perform the arithmetic. Mounjaro labelZepbound labelWegovy label
Make the site history and the observation history useful
The injection-site references use label-listed anatomical areas and a simple diagram. They keep the instruction, in the tirzepatide labels and in the Ozempic and Wegovy single-dose syringe instructions, that the back of the upper arm is for injections given by another person, and distinguish a broad region from a particular spot. The diagram is an orientation aid; the product-specific Instructions for Use remain the source for administration details and device handling. Zepbound labelMounjaro labelOzempic labelWegovy label
The side-effect references identify the study population and dose alongside each incidence figure. Hair loss, fatigue, and constipation have dedicated question pages because a short answer without the table context can imply more certainty than the source supplies. These pages report label evidence and its limitations. They do not suggest remedies, supplements, or changes to a medication schedule.
What PinPoint adds to the record
PinPoint supports injection logs with compound, dose, site, and pain level, along with reminders, a color-coded calendar, titration phases, and backfilled history. It also supports side-effect severity ratings and daily notes. Those features put recorded events and observations on dates, leaving the prescription and its clinical interpretation to the relevant healthcare conversation. App features
Vial and prefilled-pen tracking includes a supply forecast. Modeled levels are an estimate from the half-life value stored for each compound, published where a published value exists and an estimate where none does, with timestamp scrubbing and previews of a dose pattern. The app description identifies the curve as a mathematical visualization, not a personal measurement. PDF, CSV, and JSON export offer ways to review the recorded history outside the app. App features
Useful distinctions
Questions
Are these pages a personalized GLP-1 schedule?
No. The pages explain product labels and recordkeeping. A source table describes a labeled sequence or a study group, while the actual prescription and its clinical interpretation remain individual.
Where do the numbers and feature descriptions come from?
Medication facts are linked to the relevant DailyMed prescribing information. PinPoint feature descriptions are limited to its supplied App Store description. Units examples are explicitly labeled arithmetic with their inputs shown.
Your record, together
Keep the details attached to the date.
Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.
Get PinPoint on the App StoreSources & scope
Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.
- PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
- Mounjaro prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
d2d7da5d-ad07-4228-955f-cf7e355c8cc0, DailyMed SPL of 27 August 2026. - Ozempic prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
adec4fd2-6858-4c99-91d4-531f5f2a2d79, DailyMed SPL of 1 June 2026. - Rybelsus prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
27f15fac-7d98-4114-a2ec-92494a91da98, DailyMed SPL of 30 January 2026. - Saxenda prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
3946d389-0926-4f77-a708-0acb8153b143, DailyMed SPL of 25 February 2026. - Wegovy prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
ee06186f-2aa3-4990-a760-757579d8f77b, DailyMed SPL of 18 June 2026. - Zepbound prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
487cd7e7-434c-4925-99fa-aa80b1cc776b, DailyMed SPL of 28 August 2026.